Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025

Kalaris Therapeutics, Inc.

Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.
Annual base salary of $485,000; eligible for target bonus of up to 40% of base salary.
Received incentive stock option for 235,000 shares vesting over 4 years at closing price on grant date.
Severance: 9 months salary (12 months if within 12 months of change in control) plus COBRA and accelerated equity.
Gall previously CFO of iTeos Therapeutics (June 2020 – Aug 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.